









市场行情
/
股票
/
nasdaq-vnda
/

Vanda Pharmaceuticals Inc

VNDA

6.840USD

-0.190-2.70%

收盘 12/23, 16:00（美东）报价延迟15分钟

404.21M总市值

亏损市盈率 TTM



Vanda Pharmaceuticals Inc

6.840

-0.190-2.70%

概览公司财务分析

概览

公司

财务

分析

关于 Vanda Pharmaceuticals Inc 公司

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

Vanda Pharmaceuticals Inc简介



公司代码VNDA

公司名称Vanda Pharmaceuticals Inc

上市日期Apr 12, 2006

CEOPolymeropoulos (Mihael Hristos)

员工数量368

证券类型Ordinary Share

年结日Apr 12

公司地址Suite 300E

城市WASHINGTON

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编20037

电话12027343400

网址https://www.vandapharma.com/

公司代码VNDA

上市日期Apr 12, 2006

CEOPolymeropoulos (Mihael Hristos)

Vanda Pharmaceuticals Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Mihael Hristos Polymeropoulos, M.D.

Chairman of the Board, President, Chief Executive Officer

2.34M

+0.43%

Mr. Gunther Birznieks

Senior Vice President - Business Development

411.63K

+73.26%

Mr. Kevin Patrick Moran

Chief Financial Officer, Senior Vice President, Treasurer

329.46K

+118.08%

Mr. Richard W. Dugan

Lead Independent Director

177.45K

+50.09%

Dr. Tage Honore, Ph.D.

Independent Director

123.47K

+92.19%

Ms. Anne Sempowski Ward

Independent Director

119.07K

+98.97%

Dr. Stephen Ray Mitchell, M.D.

Independent Director

97.08K

+116.43%

Mr. Timothy I. Williams

Senior Vice President, General Counsel, Secretary

Ms. Phaedra S. Chrousos

Independent Director

Mr. Joakim (Kim) Wijkstrom

Senior Vice President, Chief Marketing Officer

名称

名称/职务

职务

持股

持股变动

Dr. Mihael Hristos Polymeropoulos, M.D.

Chairman of the Board, President, Chief Executive Officer

2.34M

+0.43%

Mr. Gunther Birznieks

Senior Vice President - Business Development

411.63K

+73.26%

Mr. Kevin Patrick Moran

Chief Financial Officer, Senior Vice President, Treasurer

329.46K

+118.08%

Mr. Richard W. Dugan

Lead Independent Director

177.45K

+50.09%

Dr. Tage Honore, Ph.D.

Independent Director

123.47K

+92.19%

Ms. Anne Sempowski Ward

Independent Director

119.07K

+98.97%

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Fanapt

29.29M

55.70%

Hetlioz

16.19M

30.79%

PONVORY

7.10M

13.51%

由于公司未披露，未能获取相关数据

业务

地区

业务USD

名称

营收

占比

Fanapt

29.29M

55.70%

Hetlioz

16.19M

30.79%

PONVORY

7.10M

13.51%

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

9.77%

The Vanguard Group, Inc.

6.02%

Renaissance Technologies LLC

5.88%

Millennium Management LLC

5.50%

Dimensional Fund Advisors, L.P.

4.34%

其他

68.49%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

9.77%

The Vanguard Group, Inc.

6.02%

Renaissance Technologies LLC

5.88%

Millennium Management LLC

5.50%

Dimensional Fund Advisors, L.P.

4.34%

其他

68.49%

股东类型

持股股东

占比

Investment Advisor

28.53%

Investment Advisor/Hedge Fund

27.12%

Hedge Fund

20.23%

Individual Investor

7.19%

Research Firm

1.71%

Pension Fund

0.27%

Bank and Trust

0.20%

Sovereign Wealth Fund

0.19%

Family Office

0.09%

其他

14.45%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

373

46.45M

78.60%

-9.99M

2025Q2

417

50.75M

85.90%

-11.31M

2025Q1

426

48.51M

82.37%

-12.27M

2024Q4

444

46.48M

79.71%

-15.23M

2024Q3

446

47.42M

81.36%

-14.93M

2024Q2

445

46.99M

80.73%

-18.42M

2024Q1

434

53.50M

92.97%

-11.41M

2023Q4

445

55.38M

96.27%

-9.21M

2023Q3

446

56.79M

98.75%

-12.15M

2023Q2

434

60.42M

105.19%

-10.16M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

5.99M

10.13%

-31.47K

-0.52%

Jun 30, 2025

The Vanguard Group, Inc.

3.54M

5.99%

+46.84K

+1.34%

Jun 30, 2025

Renaissance Technologies LLC

3.45M

5.83%

-118.97K

-3.34%

Jun 30, 2025

Millennium Management LLC

3.12M

5.28%

+980.75K

+45.84%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

2.59M

4.38%

+46.08K

+1.81%

Jun 30, 2025

Tang Capital Management, LLC

2.35M

3.98%

Jun 30, 2025

Polymeropoulos (Mihael Hristos)

2.34M

3.95%

+10.00K

+0.43%

Aug 07, 2025

BlackRock Financial Management, Inc.

2.43M

4.12%

+286.64K

+13.35%

Jun 30, 2025

Acadian Asset Management LLC

1.73M

2.93%

-155.16K

-8.22%

Jun 30, 2025

Two Sigma Investments, LP

1.34M

2.26%

+925.23K

+225.21%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Neuroscience and Healthcare ETF

0.49%

Invesco NASDAQ Future Gen 200 ETF

0.49%

SPDR SSGA US Small Cap Low Volatility Index ETF

0.12%

ALPS Medical Breakthroughs ETF

0.1%

Federated Hermes MDT Small Cap Core ETF

0.09%

iShares Micro-Cap ETF

0.05%

ProShares Ultra Nasdaq Biotechnology

0.04%

Franklin US Small Cap Multifactor Index ETF

0.04%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.04%

JPMorgan Diversified Return U.S. Small Cap Equity ETF

0.03%

iShares Neuroscience and Healthcare ETF

占比0.49%

Invesco NASDAQ Future Gen 200 ETF

占比0.49%

SPDR SSGA US Small Cap Low Volatility Index ETF

占比0.12%

ALPS Medical Breakthroughs ETF

占比0.1%

Federated Hermes MDT Small Cap Core ETF

占比0.09%

iShares Micro-Cap ETF

占比0.05%

ProShares Ultra Nasdaq Biotechnology

占比0.04%

Franklin US Small Cap Multifactor Index ETF

占比0.04%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

占比0.04%

JPMorgan Diversified Return U.S. Small Cap Equity ETF

占比0.03%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Vanda Pharmaceuticals Inc的前五大股东是谁？



Vanda Pharmaceuticals Inc 的前五大股东如下：
BlackRock Institutional Trust Company, N.A.持有股份：5.99M，占总股份比例：10.13%。
The Vanguard Group, Inc.持有股份：3.54M，占总股份比例：5.99%。
Renaissance Technologies LLC持有股份：3.45M，占总股份比例：5.83%。
Millennium Management LLC持有股份：3.12M，占总股份比例：5.28%。
Dimensional Fund Advisors, L.P.持有股份：2.59M，占总股份比例：4.38%。